All Articles
On June 19, 2018, the FDA revised the prescribing label for atezolizumab (Tecentriq; Genentech) and for pembrolizumab (Keytruda; Merck) to limit the use of these 2 immunotherapies in patients with locally advanced or metastatic urothelial cancer only to patients who are ineligible for cisplatin-containing chemotherapy. Read More ›
On August 16, 2018, the FDA approved lenvatinib (Lenvima; Eisai) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Read More ›
On August 16, 2018, the FDA accelerated the approval of nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with metastatic small-cell lung cancer that progressed after platinum-based chemotherapy and ≥1 other lines of therapy. Read More ›
On July 13, 2018, the FDA approved a new indication for enzalutamide (Xtandi; Astellas) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Enzalutamide was initially approved for metastatic CRPC in 2012. Read More ›
Among patients with cancer, sleep deficiency and cancer-related fatigue rank highest in prevalence and severity during all treatment phases, regardless of cancer type or stage. Read More ›
Omega-3 fatty acids significantly reduced aromatase inhibitor (AI)-induced joint pain in obese women with breast cancer, according to a new retrospective analysis of the SWOG S0927 study, a 24-week, randomized, controlled clinical trial that compared omega-3 fatty acids and placebo in patients with AI-related arthralgia. Read More ›
Patients with Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorders (PTLD) who do not respond to first-line rituximab (Rituxan) therapy are extremely difficult to manage, said Susan E. Prockop, MD, Pediatric Oncologist, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2018 European Hematology Association Congress. Read More ›